Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers

References

• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560–72
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC task force on the management of arterial hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25:1751–62
   PubMed Web of Science ®Google Scholar
• Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3–107
   PubMed Web of Science ®Google Scholar
• Taylor A, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich) 2011;13:677–86
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011;13:146–54
   PubMed Web of Science ®Google Scholar
• MacGregor GA, Viskoper JR, Antonios TF, He FJ. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. Hypertension 2000;36:454–60
   PubMed Web of Science ®Google Scholar
• Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544–9
   PubMed Web of Science ®Google Scholar
• Hasebe N, Kikuch K; for the NICE Combi Study Group. Controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445–53
   PubMed Web of Science ®Google Scholar
• Metoki H, Ohkubo T, Kikuya M, et al. The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker. J Hypertens 2012;30:1478–86
   PubMed Web of Science ®Google Scholar
• Birkenhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999;17:873–81
   PubMed Web of Science ®Google Scholar
• Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797–810
   PubMed Web of Science ®Google Scholar
• Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418–26
   PubMed Web of Science ®Google Scholar
• Maillard MP, Wurzner G, Nussberger J, et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002;71:68–76
   PubMed Web of Science ®Google Scholar
• Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41:31–6
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Poirier L, Lefebvre J, et al. Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension. Can J Cardiol 2010;26:e313–19
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92
   PubMed Web of Science ®Google Scholar
• Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of add-on low dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide versus candesartan/amlodipine. Hypertens Res 2007;30:831–7
   PubMed Web of Science ®Google Scholar
• Matsui Y, Eguchi K, O’Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009;54:716–23
   PubMed Web of Science ®Google Scholar
• Gradman AH, Brady WE, Gazdick LP, et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002;24:1049–61
   PubMed Web of Science ®Google Scholar
• Naritomi H, Fujita T, Ito S, et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens Res 2008;31:295–304
   PubMed Web of Science ®Google Scholar
• Saito I, Suzuki H, Kageyama S, Saruta T. Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan's Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE). Clin Exp Hypertens 2011;33:133–40
   PubMed Web of Science ®Google Scholar
• Kita T, Yokota N, Ichiki Y, et al. Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). Clin Exp Hypertens 2012;34:498–503
   PubMed Web of Science ®Google Scholar